You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
A 13-year real-life study on efficacy, safety and biological effects of Vespula venom immunotherapy
|
|---|---|
| Published in |
Clinical and Molecular Allergy, January 2018
|
| DOI | 10.1186/s12948-017-0079-y |
| Pubmed ID | |
| Authors |
Marcello Albanesi, Andrea Nico, Alessandro Sinisi, Lucia Giliberti, Maria Pia Rossi, Margherita Rossini, Georgios Kourtis, Anna Simona Rucco, Filomena Loconte, Loredana Muolo, Marco Zurlo, Danilo Di Bona, Maria Filomena Caiaffa, Luigi Macchia |
| Abstract |
Hymenoptera venom immunotherapy (VIT) is a clinically effective treatment. However, little is known about its long-term clinical efficacy and biological effects. Several mechanisms have been proposed to account for VIT efficacy, including reduction of specific IgE and induction of allergen-specific IgG4, but the overall picture remains elusive. We investigated Vespula VIT clinical efficacy up to 8 years after discontinuation and the kinetics of Vespula-specific IgE and IgG4. Out of 686 consecutive patients we retrospectively selected and analysed a series of 23 patients with Vespula allergy that underwent a 5-year IT course, followed by a prolonged follow-up. Clinical efficacy of VIT was assessed as number and severity of reactions to Vespula re-stinging events. The presence of Vespula-specific IgE and IgG4 was also monitored over time. During the VIT treatment, patients were protected, reporting no reactions or mild reactions in occasion of re-stinging events. This protection was entirely maintained during the follow-up, up to 8 years. Skin reactivity (reflecting mast cell-bound Vespula-specific IgE) and circulating Vespula-specific IgE levels declined substantially during VIT. Notably, this reduction was maintained over time during the follow-up. Moreover, all the patients were analysed for IgG4. A robust induction of Vespula-specific IgG4 was observed during the VIT course, with a substantial decline during the follow-up. We conclude that Vespula VIT is a clinically effective treatment, which induces long-term protection after discontinuation. The reduction of specific IgE, assessed by skin tests and RAST, closely matches the VIT- induced protection, while the IgG4 induction seems not to be associated with VIT clinical efficacy in the long term. |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 21% |
| Student > Ph. D. Student | 3 | 16% |
| Student > Master | 2 | 11% |
| Student > Bachelor | 2 | 11% |
| Researcher | 2 | 11% |
| Other | 2 | 11% |
| Unknown | 4 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 37% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 16% |
| Agricultural and Biological Sciences | 1 | 5% |
| Business, Management and Accounting | 1 | 5% |
| Psychology | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 5 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 December 2020.
All research outputs
#5,951,441
of 23,016,919 outputs
Outputs from Clinical and Molecular Allergy
#96
of 214 outputs
Outputs of similar age
#121,054
of 441,922 outputs
Outputs of similar age from Clinical and Molecular Allergy
#6
of 7 outputs
Altmetric has tracked 23,016,919 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 214 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,922 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one.